Lexicon Pharmaceuticals Inc vs ANNSD
A head-to-head of Lexicon Pharmaceuticals Inc (LXRX) and ANNSD (ANNSD) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | LXRX | ANNSD |
|---|---|---|
| Market Cap | $888.39M | $457.05B |
| P/E (TTM) | — | 12.29 |
| Forward P/E | 0.00 | 16.69 |
| P/S | 17.84 | 42.74 |
| P/B | 3.95 | 4.36 |
| EV/EBITDA | 16.57 | 10.72 |
| Dividend Yield | — | 3.20% |
| Profit Margin | -37.46% | 34.92% |
| Gross Margin | 99.45% | 73.91% |
| Operating Margin | -98.21% | 47.03% |
| Revenue Growth (YoY) | +1572.11% | +102.66% |
| FCF Yield | — | 0.27% |
| Debt / Equity | 27.43 | 52.51 |
| Current Ratio | 18.79 | 1.88 |
Which is better: Lexicon Pharmaceuticals Inc or ANNSD?
- ✓Larger by market cap: ANNSD
- ✓More profitable (net margin): ANNSD
- ✓Faster revenue growth: Lexicon Pharmaceuticals Inc
Across 9 available metrics, Lexicon Pharmaceuticals Inc leads 6–3.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Lexicon Pharmaceuticals Inc with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.